MarketFriction

Fresenius Kabi Oncology Ltd

BSE 532545 · Pharmaceuticals
Market cap₹Cr.
Not trading

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Mar 2013Jun 2013Sep 2013Dec 2013
Sales931279685
Expenses82118125121
Operating Profit118-29-37
OPM %12%7%-30%-43%
Other Income-610-6
Interest-2-5710
Depreciation7788
Profit before tax17-44-61
Tax %962%32%2%4%
Net Profit-85-45-64
EPS in Rs-0.490.30-2.83-4.02
Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Sales241257411413527596408464542624703660
Expenses215335325341505453480552546549571569
Operating Profit26-78877122143-72-88-57513290
OPM %11%-30%21%17%4.2%24%-18%-19%-0.8%12%19%14%
Other Income18037313491-5-8-34-1313-13-60
Interest822191818-313-1329374637
Depreciation51213172426314452495555
Profit before tax192-75867072115-123-154-99218-61
Tax %22%4%7%30%29%30%-10%2%-17%213%-6%-12%
Net Profit149-7880495181-111-157-83-220-54
EPS in Rs9.53-4.915.073.113.225.09-7.04-9.93-5.22-0.151.24-3.41
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth10%10%7%-6%
Compounded Profit Growth10%20%42%15%
Stock Price CAGR%%%%
Return on Equity1%-4%7%11%
Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Equity Capital161616161616161717171717
Reserves483396476526577657546505424421441390
Borrowings195242269333147140311349421521474463
Other Liabilities108120150185181226226245317260298360
Total Liabilities8027749121,0599211,0391,0981,1161,1791,2191,2311,229
Fixed Assets74196195258305352463483522494469456
CWIP12335896140163795530453837
Investments18312912912600000000
Other Assets421447529579476524556578626680724736
Total Assets8027749121,0599211,0391,0981,1161,1791,2191,2311,229
Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Cash from Operating Activity-65-555650174128-53-1218-3911298
Cash from Investing Activity1930-63-11617-121-86-44-40-29-30-52
Cash from Financing Activity49283249-196-20140164-48147-29-10
Net Cash Flow2226-16-5-131-1-79795336
Free Cash Flow-106-52-7-71647-130-158-29-797544
CFO/OP-238%69%78%92%856%109%57%137%-180%-52%89%113%
Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Debtor Days1421451341561401131009390838483
Inventory Days466679584559317543662452581579510523
Days Payable264235221219159202380261298233219301
Cash Conversion Cycle344589497496298454382283372430375305
Working Capital Days453462307337206193292261221258233213
ROCE %34%-8%13%10%6%15%-11%-14%-5%4%11%9%

Fundamentals

Market Cap₹ Cr.
Current Price₹ 132
Book Value₹ 25.7
ROCE8.61 %
ROE11.2 %
Dividend Yield0.00 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)-6%
Compounded Profit Growth (TTM)15%
Standalone figures.
Valuation
P/E, 3-year average115.21x
P/B, 3-year average5.20x
P/E, 5-year average115.21x
P/B, 5-year average5.01x
Profitability
Operating margin (excl. other income)13.70%
Operating margin (incl. other income)4.56%
EBITDA margin4.56%
Pre-tax margin-9.30%
Net profit margin-8.18%
ROE-12.47%
ROCE-2.72%
ROA-4.38%
ROE, 3-year average-2.88%
ROCE, 3-year average2.78%
ROA, 3-year average-1.00%
ROE, 5-year average-10.96%
ROCE, 5-year average-3.77%
ROA, 5-year average-4.88%
ROIC (approx.)-2.49%
Tax rate12.08%
Other income / net worth-14.82%
Growth
Sales growth (latest year)-6.24%
Profit growth (latest year)-375.38%
Sales CAGR, 3 years6.79%
Sales CAGR, 5 years10.07%
Per share
EPS (TTM)Rs -3.17
EPS (latest year)Rs -3.17
EPS, 3-year averageRs -0.72
EPS, 5-year averageRs -3.25
Book value per shareRs 23.90
Sales per shareRs 38.74
Cash flow per shareRs 5.78
Free cash flow per shareRs 2.58
Efficiency
Asset turnover0.54x
Fixed asset turnover1.44x
Inventory turnover0.91x
Inventory days401 days
Debtor days83 days
Debtors turnover4.42x
Creditor days301 days
Cash conversion cycle305 days
Working capital days213 days
Leverage
Total debtRs 463 Cr
Cash and bankRs 2 Cr
Net debtRs 461 Cr
Debt to equity1.14x
Net debt / EBITDA15.32x
Interest coverage-0.67x
Owners' fund to total sources33.09%
Debt to assets37.65%
Cash flow
Cash from Operating Activity (latest year)Rs 98 Cr
Cash from Investing Activity (latest year)Rs -52 Cr
Cash from Financing Activity (latest year)Rs -10 Cr
Net Cash Flow (latest year)Rs 36 Cr
Free cash flow (latest year)Rs 44 Cr
FCFE (approx.: FCF + change in debt)Rs 32 Cr
Sales to cash flow6.70x
Statement figures
Net sales (TTM)Rs 660 Cr
Net sales (latest year)Rs 660 Cr
Operating profit excl. other income (latest year)Rs 90 Cr
Other income (TTM)Rs -60 Cr
EBITDA (TTM)Rs 30 Cr
PBDT (TTM)Rs -7 Cr
Profit before tax (TTM)Rs -61 Cr
Tax (latest year)Rs -7 Cr
Net profit (TTM)Rs -54 Cr
Net profit (latest year)Rs -54 Cr
Depreciation (TTM)Rs 55 Cr
Interest (TTM)Rs 37 Cr
Cost of goods sold (latest year)Rs 351 Cr
Total expenditure (latest year)Rs 569 Cr
Total income (latest year)Rs 599 Cr
Share capitalRs 17 Cr
ReservesRs 390 Cr
Shareholders' fundsRs 407 Cr
Total assetsRs 1,229 Cr
Net blockRs 456 Cr
Capital work in progressRs 37 Cr
InvestmentsRs 0 Cr
ReceivablesRs 149 Cr
InventoryRs 386 Cr
Other liabilitiesRs 360 Cr
Shares outstanding (crore)17.02
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.

Red flags

F-score 4 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

No quarterly results published.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Fresenius Kabi Oncology Ltd?

Fresenius Kabi Oncology Ltd (532545) has a market capitalisation of Rs Cr. at the close.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03